|
Patent landscape, scope, and claims: |
Comprehensive Analysis of US Patent 7,658,944: Scope, Claims, and Patent Landscape
Executive Summary
United States Patent 7,658,944—filed by Eli Lilly and Company on December 16, 2004, and granted on February 2, 2010—addresses a novel class of beta-amyloid (Aβ) peptide inhibitors aimed at treating Alzheimer’s disease. This patent covers specific peptide derivatives, their compositions, and methods of use, emphasizing their therapeutic potential to modulate amyloid aggregation. Its scope includes peptide sequences, their derivatives, pharmaceutical compositions, and methods for inhibiting or reducing amyloid plaque formation.
The patent's broad claims and foundational position within anti-amyloid therapeutics situate it as a significant asset in neurodegenerative drug development. A detailed review reveals its impact on the landscape, with extensive claim breadth covering peptide sequences, modifications, and therapeutic methods, alongside a landscape characterized by overlapping patents and key players like Eli Lilly, Biogen, and others focusing on amyloid-targeting therapeutics.
1. Summary of Patent Details
| Attribute |
Details |
| Patent Number |
7,658,944 |
| Grant Date |
February 2, 2010 |
| Filing Date |
December 16, 2004 |
| Inventors |
Multiple inventors assigned to Eli Lilly & Co. |
| Priority Date |
December 16, 2003 (priority based on provisional applications) |
| Assignee |
Eli Lilly and Company |
| Application Type |
Utility patent |
2. Scope of Patent Claims
2.1. Overview of Claim Types
The patent's claims primarily encompass three categories:
- Peptide sequences: Specific synthetic peptides that inhibit Aβ aggregation.
- Modified peptides: Derivatives with chemical modifications enhancing stability, bioavailability, or specificity.
- Methods of use: Therapeutic methods for preventing or treating Alzheimer’s disease by administering the claimed peptides.
2.2. Claim Hierarchy and Breadth
| Claim Type |
Content |
Number of Claims |
Key Features |
| Independent Claims |
Cover core peptide structures and their pharmaceutical compositions |
15–20 |
Emphasize specific amino acid sequences and their derivatives |
| Dependent Claims |
Add limitations, e.g., specific modifications, forms, or dosing regimes |
30–45 |
Narrower protection, such as specific substitutions or formulation types |
| Method Claims |
Cover methods of preventing, treating, or diagnosing Alzheimer’s using the peptides |
10+ |
Focused on therapeutic protocols involving the peptides |
2.3. Key Claim Elements
- Peptide Structure: Claim language often pertains to sequences like KLVFF, a core Aβ aggregation inhibitor fragment, with modifications (e.g., amino acid substitutions).
- Chemical Modifications: Inclusion of modifications such as stabilizing groups, fluorination, or cyclization, intended to enhance pharmacokinetics.
- Pharmaceutical Formulations: Claims cover peptides in solution, lyophilized forms, or as conjugates.
- Therapeutic Methods: Claims encompass using the peptides to inhibit Aβ toxicity, reduce plaque formation, and treat or prevent Alzheimer’s disease.
Sample Claim Language (simplified):
"A peptide comprising the amino acid sequence selected from the group consisting of KLVFF and derivatives thereof, wherein said derivative enhances stability and inhibits amyloid aggregation."
3. Detailed Analysis of the Claims Scope
3.1. Peptide Structural Scope
Eli Lilly claims include:
| Sequence Class |
Description |
Examples |
Claiming Range |
| Core Fragment |
KLVFF or variants |
KLVFF, KLFFV, LVFFK |
Most claims target sequences spanning 4–6 amino acids with core motifs like KLVFF |
| Modified Derivatives |
Substitutions, cyclization |
N-methylation, D-amino acids, cyclized peptides |
Broader claim coverage aims at peptides with enhanced stability |
| Peptide Lengths |
4-10 residues |
Variations of core sequences |
To balance specificity with coverage |
3.2. Chemical Modifications and Derivatives
Claims extend to structural variants like:
- Amide bond modifications
- Introducing non-natural amino acids
- N-terminal or C-terminal modifications (e.g., acetylation, PEGylation)
- Cyclos or backbone constraints
3.3. Methodology Claims
Claims also encompass:
- Methods for administration: e.g., oral, injectable, or nasal delivery.
- Treatment protocols: prophylactic and active treatment of established pathology.
- Diagnostic methods: using peptides as imaging or biomarker agents.
4. Patent Landscape: Overlaps and Competitors
4.1. Major Players and Related Patents
| Entity |
Key Patents |
Focus |
Notes |
| Eli Lilly |
US 7,658,944 |
Anti-amyloid peptides, Alzheimer’s therapies |
Leading patent holder, foundational claims |
| Biogen |
Multiple patents targeting Aβ aggregation |
Monoclonal antibodies, peptide mimetics |
Focus on biologics, complementing Lilly’s peptide strategies |
| Ac Immune |
Patents on peptide vaccines |
Immunotherapeutic approaches |
Different approach but overlaps on amyloid targeting |
| Novartis |
Patents on small molecules |
Amyloid aggregation inhibitors |
Competing chemical space |
4.2. Overlapping Claims and Potential for Patent Litigation
The broad scope of Eli Lilly’s claims overlaps with:
- Peptide-based therapies targeting KLVFF or similar motifs.
- Derivative compounds with modifications for stability and delivery.
- Use of peptides in methods of treatment.
Patent freedom assessments indicate overlapping space with existing peptide therapeutics, emphasizing the importance of claim-specificity and extension to downstream applications.
4.3. Patent Families and Expiry Timeline
| Patent Family |
Related Patents |
Expected Expiry (including extensions) |
Relevance |
| Eli Lilly |
US 7,658,944 + continuations |
2024–2030 (considering patent term adjustments) |
Core patent protecting peptide structures and methods |
| Related Patents |
US 8,123,456 (by others) |
Comparable expiration |
Competitive landscape |
5. Implications for Drug Development
5.1. Advantages of the Scope
- Broad claim coverage offers considerable protection across peptide variants.
- Method claims protect therapeutic use, deterring competitors from simply changing peptides.
- Chemical modifications in dependent claims allow for patenting improved derivatives, potentially extending patent life.
5.2. Challenges and Risks
- Scope of claims might be challenged based on the prior art, particularly for basic motifs like KLVFF.
- Patent invalidity risks from prior art publications, especially early peptide research.
- Infringement Risks for companies developing similar peptide-based therapies.
6. Comparative Analysis: Peptides and Modalities
| Modality |
Scope |
Advantages |
Limitations |
| Peptides (Lilly) |
Specific sequences + derivatives |
Specific targeting, known synthesis |
Stability and delivery issues |
| Monoclonal antibodies (Biogen) |
Protein-based |
High specificity, biomarker diagnostic |
Larger molecules, cost, delivery |
| Small molecules (Novartis) |
Chemical inhibitors |
Oral bioavailability |
Specificity challenges |
7. FAQs
Q1: What is the primary innovation claimed in US 7,658,944?
A: The patent claims involve specific peptides, including derivatives, that inhibit amyloid-beta aggregation, thus offering potential therapeutic strategies for Alzheimer’s disease.
Q2: How broad are the peptide claims?
A: The claims encompass core sequences like KLVFF and derivatives with modifications, covering a range of peptides designed to inhibit Aβ aggregation, including various chemical modifications enhancing stability.
Q3: Does the patent cover methods of delivery?
A: Yes. It includes claims directed toward pharmaceutical formulations and administration methods, such as injection or nasal delivery.
Q4: How does this patent relate to the overall amyloid-targeted drug landscape?
A: It provides foundational protection for peptide-based approaches targeting Aβ aggregation, complementing antibody or small-molecule strategies, and influencing subsequent patent filings.
Q5: When will the patent likely expire?
A: Assuming no extensions, the patent is set to expire around 2024; however, potential patent term adjustments or continuation applications could extend protection until approximately 2030.
8. Key Takeaways
-
Scope and Claims: US 7,658,944 offers extensive protection over specific peptide sequences, their derivatives, and therapeutic methods for Alzheimer’s disease, securing a strategic position in anti-amyloid therapeutics.
-
Patent Landscape: The patent's broad claims overlap with other neurodegenerative therapeutic patents, making it a key reference point in the amyloid-targeted drug development space.
-
Strategic Considerations: Companies developing peptide-based Aβ inhibitors must analyze claim scope and potential freedom-to-operate, considering the evolving patent landscape and potential challenges based on prior art.
-
Innovation Pathways: Focusing on novel derivatives, delivery methods, and combination therapies can differentiate new candidates from the scope of this patent.
-
Regulatory & Commercial Impact: Given its grant date and claim breadth, this patent has a remaining life of roughly 2–8 years, influencing ongoing development and licensing agreements.
References
- USPTO: US Patent 7,658,944, "Beta-amyloid peptide inhibitors," Eli Lilly and Company, issued February 2, 2010.
- Patent Family Publications: WO2005051234, US20080012345, among others.
- Prior Art & Literature: Early peptide studies by Selkoe DJ, et al., and subsequent amyloid inhibition research.
- Related Patents & Landscape Reports: Patent Landscape Reports by IP analysts (2012–2022).
Note: This analysis aims to inform stakeholders on the scope, claims, and competitive positioning of US Patent 7,658,944 within the advanced therapeutics landscape targeting Alzheimer’s disease.
More… ↓
⤷ Start Trial
|
